V. M. Manning & CO. Inc. Purchases Shares of 19,849 Abbott Laboratories $ABT

V. M. Manning & CO. Inc. purchased a new position in shares of Abbott Laboratories (NYSE:ABT) in the second quarter, according to its most recent filing with the SEC. The firm purchased 19,849 shares of the healthcare product maker’s stock, valued at approximately $1,801,000. Abbott Laboratories accounts for 1.5% of V. M. Manning & CO. Inc.’s portfolio, making the stock its 11th largest holding.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Nia Impact Advisors LLC grew its stake in Abbott Laboratories by 2.2% during the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after purchasing an additional 79 shares during the period. Riggs Asset Managment Co. Inc. lifted its stake in Abbott Laboratories by 9.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock valued at $140,000 after buying an additional 88 shares during the period. GHP Investment Advisors Inc. boosted its holdings in shares of Abbott Laboratories by 0.3% during the 4th quarter. GHP Investment Advisors Inc. now owns 29,411 shares of the healthcare product maker’s stock worth $3,685,000 after buying an additional 92 shares in the last quarter. Eley Financial Management Inc increased its stake in shares of Abbott Laboratories by 0.9% in the 4th quarter. Eley Financial Management Inc now owns 10,817 shares of the healthcare product maker’s stock valued at $1,355,000 after acquiring an additional 92 shares in the last quarter. Finally, Copley Financial Group Inc. increased its stake in shares of Abbott Laboratories by 2.1% in the 4th quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker’s stock valued at $556,000 after acquiring an additional 93 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Stock Up 1.1%

Shares of NYSE ABT opened at $110.92 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The company has a 50-day moving average price of $96.86 and a 200-day moving average price of $99.73. The stock has a market capitalization of $191.93 billion, a P/E ratio of 35.90, a P/E/G ratio of 2.12 and a beta of 0.59. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is presently 81.55%.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Bank of America issues a Buy rating: The endorsement from Bank of America Securities adds to positive Wall Street sentiment and may support investor confidence in Abbott’s earnings and growth outlook. Abbott Laboratories Receives a Buy from Bank of America Securities
• Positive Sentiment: Abbott and Google expand glucose-monitoring partnership: Abbott will integrate Lingo glucose data with Google’s AI-driven consumer health tools. The companies also plan a large real-world metabolic-health study, potentially improving personalized coaching, supporting future Lingo features and increasing the commercial value of Abbott’s biowearable platform. Abbott Laboratories Ties Lingo Glucose Data to AI Health Tools
• Positive Sentiment: Potential cardiovascular innovation: Abbott’s ongoing PULSE study is evaluating early treatment for atrial fibrillation. Positive results could strengthen Abbott’s electrophysiology portfolio, although the study remains a longer-term catalyst and does not yet establish a commercial benefit. Early AF Treatment on Trial: What Abbott’s PULSE Study Could Mean for Investors
• Neutral Sentiment: Blood-donation campaign returns: Abbott and the Big Ten revived the “We Give Blood” campaign amid a U.S. blood shortage. The initiative enhances Abbott’s public profile and reinforces its healthcare mission, but it is unlikely to have a material near-term effect on earnings. Abbott and Big Ten Bring Back We Give Blood

Analyst Ratings Changes

Several brokerages recently issued reports on ABT. Jefferies Financial Group cut their target price on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Leerink Partners dropped their price objective on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a report on Tuesday, April 21st. UBS Group reduced their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Raymond James Financial decreased their target price on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Finally, Barclays cut their price target on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $118.17.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.